A final clinical report for a Phase II pharmacokinetic study on LTR Pharma’s (ASX: LTP) Spontan fast-acting intranasal spray to treat erectile dysfunction (ED...
Market Samachar is a news aggregator. This article was originally published by smallcaps.com.au. Tap the button above to read the full story on their site.